|
|
|
|
Alzheimer's gene changes brain early, study finds
A gene known to raise the risk of Alzheimer's disease may alter brain activity throughout life, British researchers say.Photograph by: File photo, Reuters WASHINGTON (Reuters) - A gene known to raise the risk of Alzheimer's...
|
|
|
J&J Takes On Alzheimer's Disease With $1B Stake In Elan
The two will cooperate to complete research on two injected drugs to stop progression of the mind-robbing disease and on a vaccine to prevent the buildup of plaque in the brain that causes increasing memory loss, confusion, wandering and...
|
|
|
Elan takeover more likely after Johnsons deal
Elan and Johnson & Johnson's stake deal has made an outright acquisition of our top ranked biotech takeover candidate more plausible Johnson & Johnson is taking a major stake in Elan Corp in order to gain access to the latter firm's ...
|
|
|
J&J acquires rights to Elan's Alzheimer's immunotherapy program
(Datamonitor via COMTEX) -- JNJ | Quote | Chart | News | PowerRating -- Johnson & Johnson and Elan, a neuroscience-based biotechnology company, have signed a definitive agreement whereby Johnson & Johnson will acquire...
|
|
|
J&J invests heavily in Alzheimer's field
TRENTON, N.J.Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program
- First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline - Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE:...
|
|
|
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program
- First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline - Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE:...
|
|
|
Johnson & Johnson pays $1B for stake in drugmaker developing Alzheimer's treatment
Daniel Hulshizer/The Associated PressJohnson & Johnson corporate headquarters in New Brunswick.NEW BRUNSWICK -- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's...
|
|
|
J&J pays $1B for 18 percent stake in Elan, acquires interest in Alzheimer's drug candidates
LINDA A.JOHNSON AP Business Writer TRENTON, N.J. (AP) Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company...
|
|
|
J&J pays $1B for 18% stake in Elan, acquires interest in Alzheimer's drug candidates
TRENTON, N.J.(AP) - Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson pays $1B for Elan stake
Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.The two...
|
|
|
J&J pays $1B for stake in Elan
TRENTON Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.
|
|
|
Johnson & Johnson pays $1B for Elan stake
Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.The...
|
|
|
Johnson & Johnson Pays $1B For Elan Stake
TRENTON, N.J.-- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J.Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J.- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J.Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Stem cell reverses memory decline, biotechnology news
A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A....
|
|
|
Johnson & Johnson pays $1B for Elan stake
By LINDA A.JOHNSON TRENTON, N.J. (AP) -- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp.,...
|
|
|
Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J.-- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J.-- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
|
|
Johnson & Johnson to take stake in Elan
The firms will work jointly on Alzheimer's drugs and a vaccine.Associated Press Trenton, N.J. -- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a...
|
|
|
Johnson & Johnson pays $1B for Elan stake
Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.The two...
|
|
|
Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J.(AP) -- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5...
|
|
|
Johnson & Johnson Pays $1B For Elan Stake
TRENTON, N.J.-- Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion...
|
